Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inhaled Corticosteroid Clear all
Completed Not applicable Interventional

Effect of an Inhaled Corticosteroid on Airway Gene Expression in Asthma

NCT00187499
View directory record Official record
Conditions
Asthma
Interventions
Inhaled fluticasone 500 ug BID for 8 weeks
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist

NCT01914757
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
81
States / cities
Andalusia, Alabama • Birmingham, Alabama • Flagstaff, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

Budesonide Inhalation Suspension for Acute Asthma in Children

NCT00393367
View directory record Official record
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

NCT01397162
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate, Placebo, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled Asthma

NCT01730027
View directory record Official record
Conditions
Asthma
Interventions
ADC3680, Placebo, montelukast
Drug
Lead sponsor
Pulmagen Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Huntington Beach, California • Riverside, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mentored Patient-Oriented Research Career Development Award

NCT00203684
View directory record Official record
Conditions
Asthma, Distal Lung Inflammation
Interventions
Flunisolide-HFA, Flunisolide-CFC
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02141854
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
85
States / cities
Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma

NCT00048022
View directory record Official record
Conditions
Asthma
Interventions
Dual Integrin Antagonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
59
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Sep 23, 2026, 8:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Approach to Predict Steroid Sensitivity in Patients With Asthma

NCT00811278
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

NCT05110976
View directory record Official record
Conditions
Asthma
Interventions
AZD8630, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
18
States / cities
Tempe, Arizona • Bakersfield, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 23, 2026, 8:14 PM EDT
Completed No phase listed Observational

Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma

NCT01362621
View directory record Official record
Conditions
Moderate to Severe Allergic Asthma
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
50
States / cities
Birmingham, Alabama • Crescent City, California • Fresno, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)

NCT01142947
View directory record Official record
Conditions
Asthma
Interventions
beclomethasone dipropionate
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
12 Years to 56 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 23, 2026, 8:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers

NCT05111262
View directory record Official record
Conditions
Asthma, Nonadherence, Medication
Interventions
Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

NCT01928771
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
110
States / cities
Foley, Alabama • Huntsville, Alabama • Mobile, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

NCT00330070
View directory record Official record
Conditions
Asthma
Interventions
IPL512,602 20 mg once daily, IPL512,602 Matching Placebo once daily
Drug
Lead sponsor
Inflazyme Pharmaceuticals Ltd
Industry
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2007 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Heart Rate Variability Biofeedback: It's Role in Asthma Therapeutics

NCT02766374
View directory record Official record
Conditions
Asthma
Interventions
Heart rate variability biofeedback, Placebo
Behavioral
Lead sponsor
Fred Wamboldt, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
2
States / cities
Denver, Colorado • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

NCT01436110
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate 50mcg, Fluticasone propionate 100mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Los Angeles, California • Rolling Hills Estates, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01090024
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Huntington Beach, California • Mission Viejo, California • Stockton, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 4 Interventional Results available

Study of Safety of Foradil in Patients With Persistent Asthma

NCT01845025
View directory record Official record
Conditions
Persistent Asthma
Interventions
Formoterol 12 mcg, Fluticasone propionate 100 mcg, Fluticasone propionate 250 mcg, Fluticasone propionate 500 mcg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
827 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
27
States / cities
Avondale, Arizona • North Hollywood, California • Bradenton, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

NCT01867125
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
53
States / cities
Pell City, Alabama • Tucson, Arizona • Fountain Valley, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

A Study To Determine The Effect Of SB-480848 On Asthma

NCT00368576
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB 480848, tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Cypress, California • Normal, Illinois • North Dartmouth, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 23, 2026, 8:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348
View directory record Official record
Conditions
Eosinophilic Granulomatous Vasculitis
Interventions
Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

NCT02336425
View directory record Official record
Conditions
Asthma
Interventions
QGE031, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Kingwood, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 23, 2026, 8:14 PM EDT